Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration

J Fric, M Marek, V Hruskova, V Holan, J Forstova

. 2008 ; 26 (26) : 3242-3251.

Jazyk angličtina Země Nizozemsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc11004112
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
ScienceDirect (archiv) od 1993-01-01 do 2009-12-31

Mouse polyomavirus (MPyV) VP1-pseudocapsids carrying enhanced green fluorescent protein (EGFP-VLPs) were used for intranasal immunization of mice. EGFP-VLPs induced strong anti-VP1 but not anti-EGFP antibody production. In vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells (BMDCs) induced remarkable T-cell proliferative response specific for both VP1 and EGFP antigen and IL-2 and IFN-gamma production. Surprisingly, no specific cytotoxic activities against VP1 and EGFP proteins were detected. After intranasal administration of EGFP-VLPs, as well as after polyomavirus infection, a moderate reduction of CD4(+)CD25(+)Foxp3(+) T cells was observed in spleens but not in lymph nodes and peripheral blood, suggesting that both MPyV virions and pseudocapsids are able to induce changes in distribution of regulatory T cells. Treatment of EGFP-VLPs pulsed BMDCs with inhibitors of endosomal acidification proved that presentation of peptides on MHCgp class II is dependent on acidic endosomal environment. Substantial decrease of CD4-specific T-cell proliferation in the presence of proteasome inhibitor suggests that MHCgp class II might load VPL-derived peptides processed by proteasomes. Thus, polyomavirus derived VLPs appear to be promising delivery and adjuvant vehicles for therapeutic proteins.

Citace poskytuje Crossref.org

000      
03413naa 2200529 a 4500
001      
bmc11004112
003      
CZ-PrNML
005      
20121130100154.0
008      
110303s2008 ne e eng||
009      
AR
024    __
$a 10.1016/j.vaccine.2008.04.006 $2 doi
035    __
$a (PubMed)18468739
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Frič, Jan $7 xx0106155
245    10
$a Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration / $c J Fric, M Marek, V Hruskova, V Holan, J Forstova
314    __
$a Faculty of Science, Charles University in Prague, Prague 2, Czech Republic.
520    9_
$a Mouse polyomavirus (MPyV) VP1-pseudocapsids carrying enhanced green fluorescent protein (EGFP-VLPs) were used for intranasal immunization of mice. EGFP-VLPs induced strong anti-VP1 but not anti-EGFP antibody production. In vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells (BMDCs) induced remarkable T-cell proliferative response specific for both VP1 and EGFP antigen and IL-2 and IFN-gamma production. Surprisingly, no specific cytotoxic activities against VP1 and EGFP proteins were detected. After intranasal administration of EGFP-VLPs, as well as after polyomavirus infection, a moderate reduction of CD4(+)CD25(+)Foxp3(+) T cells was observed in spleens but not in lymph nodes and peripheral blood, suggesting that both MPyV virions and pseudocapsids are able to induce changes in distribution of regulatory T cells. Treatment of EGFP-VLPs pulsed BMDCs with inhibitors of endosomal acidification proved that presentation of peptides on MHCgp class II is dependent on acidic endosomal environment. Substantial decrease of CD4-specific T-cell proliferation in the presence of proteasome inhibitor suggests that MHCgp class II might load VPL-derived peptides processed by proteasomes. Thus, polyomavirus derived VLPs appear to be promising delivery and adjuvant vehicles for therapeutic proteins.
650    _2
$a aplikace intranazální $7 D000281
650    _2
$a zvířata $7 D000818
650    _2
$a protilátky virové $x krev $7 D000914
650    _2
$a krev $x imunologie $7 D001769
650    _2
$a virové plášťové proteiny $x aplikace a dávkování $x imunologie $7 D036022
650    _2
$a proliferace buněk $7 D049109
650    _2
$a cytotoxické testy imunologické $7 D003601
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zelené fluorescenční proteiny $x imunologie $7 D049452
650    _2
$a interferon gama $x biosyntéza $7 D007371
650    _2
$a interleukin-2 $x biosyntéza $7 D007376
650    _2
$a lymfatické uzliny $x imunologie $7 D008198
650    _2
$a myši $7 D051379
650    _2
$a Polyomavirus $x imunologie $7 D011120
650    _2
$a rekombinantní fúzní proteiny $x aplikace a dávkování $x imunologie $7 D011993
650    _2
$a slezina $x imunologie $7 D013154
650    _2
$a T-lymfocyty - podskupiny $x imunologie $7 D016176
650    _2
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a cytotoxické T-lymfocyty $x imunologie $7 D013602
650    _2
$a vakcíny VLP $x aplikace a dávkování $x imunologie $7 D022721
650    _2
$a financování organizované $7 D005381
700    1_
$a Marek, Martin. $7 _AN029554
700    1_
$a Hrušková, Veronika. $7 xx0228115
700    1_
$a Holáň, Vladimír, $d 1950- $7 nlk20050169384
700    1_
$a Forstová, Jitka, $d 1944- $7 xx0057861
773    0_
$t Vaccine $w MED00004631 $g Roč. 26, č. 26 (2008), s. 3242-3251 $x 0264-410X
910    __
$a ABA008 $b x $y 1
990    __
$a 20110414092513 $b ABA008
991    __
$a 20121130100223 $b ABA008
999    __
$a ok $b bmc $g 831451 $s 696140
BAS    __
$a 3
BMC    __
$a 2008 $b 26 $c 26 $d 3242-3251 $i 0264-410X $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a 2011-3B/ipme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...